Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction

[1]  K. Okumura,et al.  Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction , 2007, Heart and Vessels.

[2]  J. Karliner,et al.  Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. , 2007, American journal of physiology. Heart and circulatory physiology.

[3]  Kenneth McDonald,et al.  Diastolic Heart Failure: Evidence of Increased Myocardial Collagen Turnover Linked to Diastolic Dysfunction , 2007, Circulation.

[4]  Francis G Spinale,et al.  Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. , 2006, Journal of cardiac failure.

[5]  Arantxa González,et al.  Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. , 2006, Journal of the American College of Cardiology.

[6]  A. Baker,et al.  Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. , 2006, Cardiovascular research.

[7]  E. Maltezos,et al.  Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. , 2005, The American journal of cardiology.

[8]  G. Keren,et al.  Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. , 2005, American heart journal.

[9]  F. Veglia,et al.  Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. , 2005, European heart journal.

[10]  A. Naim,et al.  Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. , 2004, Clinical and investigative medicine. Medecine clinique et experimentale.

[11]  Pamela S Douglas,et al.  Acc/aha/ase 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article a Report of the American College of Cardiology/american Heart Association Task Force on Practice Guidelines (acc/aha/ase Committee to Update the 1997 Guidelines for the Clinical Application of Echocar , 2003 .

[12]  C. Brunelli,et al.  Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure , 2003, European journal of clinical investigation.

[13]  M. Hori,et al.  Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. , 2003, Cardiovascular research.

[14]  J. Burnett,et al.  Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases , 2002, Circulation research.

[15]  Anita Deswal,et al.  Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. , 2002, Journal of cardiac failure.

[16]  W. Hundley,et al.  Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. , 2002, JAMA.

[17]  D. Brutsaert,et al.  New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. , 2002, Circulation.

[18]  R. Visse,et al.  Matrix Metalloproteinases Regulation and Dysregulation in the Failing Heart , 2002 .

[19]  D. Brutsaert,et al.  New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. , 2002, Circulation.

[20]  F. Spinale,et al.  A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure , 2000, Circulation.

[21]  J. D’Armiento,et al.  Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. , 2000, The Journal of clinical investigation.

[22]  W. Colucci,et al.  Interleukin-1β and Tumor Necrosis Factor-α Decrease Collagen Synthesis and Increase Matrix Metalloproteinase Activity in Cardiac Fibroblasts In Vitro , 2000 .

[23]  F. Spinale,et al.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. , 1998, Circulation research.

[24]  D. Kass,et al.  Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II. , 1998, Circulation research.

[25]  Richard P. Lewis,et al.  ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardio , 1997, Circulation.

[26]  Y. Okada,et al.  A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[27]  Y. Okada,et al.  A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 8 (neutrophil collagenase) using monoclonal antibodies. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[28]  J. Covell,et al.  Collagen characterization in volume-overload- and pressure-overload-induced cardiac hypertrophy in minipigs. , 1993, The American journal of physiology.

[29]  Richard P. Lewis,et al.  ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Clinical Application of Echocard , 1990, Circulation.

[30]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[31]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[32]  W. Colucci,et al.  Matrix Metalloproteinase Activity in Cardiac Fibroblasts In Vitro Decrease Collagen Synthesis and Increase α and Tumor Necrosis Factor-β Interleukin-1 , 2000 .

[33]  W. Paulus.  European Study Group on Diastolic Heart Failure , 1998 .

[34]  Thierry C. Gillebert,et al.  How to diagnose diastolic heart failure , 1998 .

[35]  Y. Okada,et al.  A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 1 (interstitial collagenase) using monoclonal antibodies. , 1993, Clinica chimica acta; international journal of clinical chemistry.